Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.640
Low
75.00
Averages
110.50
High
125.00
Current: 52.640
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit, urging those who purchased stock between March 26 and November 4, 2025, to submit their losses before the May 5, 2026 deadline.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including potential fluid retention and heart failure in children, which could severely impact the company's reputation and stock performance.
- Data Integrity Issues: A report from activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the integrity of the company's clinical data and potentially undermining investor confidence.
- Stock Price Volatility: Following the November 4, 2025 financial report, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, reflecting the market's deep concerns regarding the company's operational viability and future prospects.
See More
Soleno Therapeutics Shareholder Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status, which is not required for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which has materially impacted the drug's commercial viability.
- Increased Risk Factors: As a result of the aforementioned concealment, the administration of DCCR poses greater safety risks in treating individuals with PWS, potentially leading to higher patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational damage, which could adversely affect the company's market performance.
- Shareholder Registration Deadline: Shareholders must register for the class action by May 5, 2026, to avoid losing their right to claim, with the Gross Law Firm offering portfolio monitoring services to keep investors updated on the case's progress.
See More
Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Reminder: Hagens Berman law firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, of the upcoming lead plaintiff deadline on May 5, 2026, urging affected investors to submit their losses promptly.
- Concealed Safety Risks: The class action against Soleno alleges that the company misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which resulted in a 27% stock price drop in a single day, reflecting market disappointment in the company's outlook.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information about Soleno to consider assisting in the investigation; under the new whistleblower program, those providing original information may receive rewards of up to 30% of any successful SEC recovery, incentivizing investor participation.
See More
Soleno Therapeutics Securities Class Action Update
- Lawsuit Background: Soleno Therapeutics is facing a securities class action for allegedly concealing safety risks associated with DCCR, affecting institutional investors who held shares from March 26 to November 4, 2025, which may impact stock price and market trust.
- FDA Approved Product: Soleno's sole commercial product, VYKAT XR, received FDA approval on March 26, 2025, for treating hyperphagia in Prader-Willi syndrome patients, despite safety concerns that could affect future sales.
- Investor Responsibilities: Institutional investors holding SLNO shares must evaluate their fiduciary obligations to participate in the lawsuit, especially following the secondary public offering of over 2.7 million shares in July 2025, which may expose them to increased financial risks.
- Litigation Impact Assessment: The lawsuit alleges that Soleno misrepresented safety issues during clinical trials, potentially leading to decreased investor confidence in the company's future, adversely affecting its market performance and financing capabilities.
See More
Soleno Therapeutics Class Action Reminder for Investors
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit due to safety issues related to its DCCR drug, with investors who purchased stock between March 26, 2025, and November 4, 2026, potentially seeking to recover losses.
- Stock Price Volatility: On August 15, 2025, Soleno's stock price dropped 11.98% to $68.09 over two days following a report from Scorpion Capital, indicating market concerns regarding the drug's safety.
- Significant Disclosure: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, causing the stock price to decline by 19.21% to $56.72 over two days, further exacerbating investor losses.
- Financial Impact: On November 4, 2025, Soleno reported financial results indicating that DCCR's market launch was disrupted, leading to a 26.59% drop in stock price to $46.87, reflecting a severe loss of investor confidence in the company's future prospects.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit, urging those who purchased stock between March 26 and November 4, 2025, to submit their losses before the May 5, 2026 deadline.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including potential fluid retention and heart failure in children, which could severely impact the company's reputation and stock performance.
- Data Integrity Issues: A report from activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the integrity of the company's clinical data and potentially undermining investor confidence.
- Stock Price Volatility: Following the November 4, 2025 financial report, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, reflecting the market's deep concerns regarding the company's operational viability and future prospects.
See More
Soleno Therapeutics Shareholder Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Soleno Therapeutics, encouraging those who purchased SLNO shares between March 26, 2025, and November 4, 2025, to contact the firm regarding potential lead plaintiff status, which is not required for recovery participation.
- Safety Concerns Allegations: The complaint alleges that Soleno downplayed and concealed significant safety concerns related to its DCCR product during Phase 3 clinical trials, including issues of excess fluid retention in participants, which has materially impacted the drug's commercial viability.
- Increased Risk Factors: As a result of the aforementioned concealment, the administration of DCCR poses greater safety risks in treating individuals with PWS, potentially leading to higher patient discontinuation rates, prescriber reluctance, adverse regulatory actions, and reputational damage, which could adversely affect the company's market performance.
- Shareholder Registration Deadline: Shareholders must register for the class action by May 5, 2026, to avoid losing their right to claim, with the Gross Law Firm offering portfolio monitoring services to keep investors updated on the case's progress.
See More
Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Reminder: Hagens Berman law firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, of the upcoming lead plaintiff deadline on May 5, 2026, urging affected investors to submit their losses promptly.
- Concealed Safety Risks: The class action against Soleno alleges that the company misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which resulted in a 27% stock price drop in a single day, reflecting market disappointment in the company's outlook.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information about Soleno to consider assisting in the investigation; under the new whistleblower program, those providing original information may receive rewards of up to 30% of any successful SEC recovery, incentivizing investor participation.
See More
Soleno Therapeutics Securities Class Action Update
- Lawsuit Background: Soleno Therapeutics is facing a securities class action for allegedly concealing safety risks associated with DCCR, affecting institutional investors who held shares from March 26 to November 4, 2025, which may impact stock price and market trust.
- FDA Approved Product: Soleno's sole commercial product, VYKAT XR, received FDA approval on March 26, 2025, for treating hyperphagia in Prader-Willi syndrome patients, despite safety concerns that could affect future sales.
- Investor Responsibilities: Institutional investors holding SLNO shares must evaluate their fiduciary obligations to participate in the lawsuit, especially following the secondary public offering of over 2.7 million shares in July 2025, which may expose them to increased financial risks.
- Litigation Impact Assessment: The lawsuit alleges that Soleno misrepresented safety issues during clinical trials, potentially leading to decreased investor confidence in the company's future, adversely affecting its market performance and financing capabilities.
See More
Soleno Therapeutics Class Action Reminder for Investors
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit due to safety issues related to its DCCR drug, with investors who purchased stock between March 26, 2025, and November 4, 2026, potentially seeking to recover losses.
- Stock Price Volatility: On August 15, 2025, Soleno's stock price dropped 11.98% to $68.09 over two days following a report from Scorpion Capital, indicating market concerns regarding the drug's safety.
- Significant Disclosure: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, causing the stock price to decline by 19.21% to $56.72 over two days, further exacerbating investor losses.
- Financial Impact: On November 4, 2025, Soleno reported financial results indicating that DCCR's market launch was disrupted, leading to a 26.59% drop in stock price to $46.87, reflecting a severe loss of investor confidence in the company's future prospects.
See More
